Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 11,136 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier sold 11,136 shares of the business’s stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $33.21, for a total transaction of $369,826.56. Following the completion of the transaction, the director now owns 11,136 shares of the company’s stock, valued at $369,826.56. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scholar Rock Price Performance

SRRK opened at $35.81 on Thursday. The company has a fifty day moving average price of $31.92 and a two-hundred day moving average price of $35.88. The firm has a market capitalization of $3.40 billion, a PE ratio of -14.15 and a beta of 0.28. Scholar Rock Holding Corporation has a 52 week low of $6.76 and a 52 week high of $46.98. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company posted ($0.59) earnings per share. As a group, analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors have recently modified their holdings of the stock. FMR LLC boosted its stake in Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company’s stock worth $589,316,000 after acquiring an additional 3,439,215 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company’s stock worth $401,231,000 after purchasing an additional 629,315 shares during the period. Vanguard Group Inc. boosted its position in shares of Scholar Rock by 2.1% during the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company’s stock worth $155,773,000 after purchasing an additional 101,723 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock valued at $127,301,000 after buying an additional 2,732,546 shares during the period. Finally, Bellevue Group AG increased its position in shares of Scholar Rock by 16.2% in the 4th quarter. Bellevue Group AG now owns 2,510,690 shares of the company’s stock valued at $108,512,000 after buying an additional 349,487 shares in the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on SRRK. Wedbush reissued an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, June 18th. Lifesci Capital upgraded Scholar Rock to a “strong-buy” rating in a report on Tuesday, June 3rd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Scholar Rock has a consensus rating of “Buy” and an average price target of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.